<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadline</th>
</tr>
</thead>
</table>
| Clinical Consortium Award             | The Operations Center PI must be an independent investigator at or above the level of Associate Professor (or equivalent) with experience in developing and running large scale initiatives such as clinical trials or consortia. Additional criteria are described in the announcement.                                                                 | - The NFRP Clinical Trial Consortium requires collaboration of multiple organizations and individuals for the purpose of rapidly executing clinical trials. Therefore, the offeror must have a demonstrated history of large scale collaborative research.  
- This award will be issued as a Research Other Transaction Agreement (rOTA).  
- The objectives of the rOTA are the conception, design, development, and conduct of collaborative Phase I and II clinical evaluations of promising therapeutic agents for the management or treatment of NF1, NF2, and schwannomatosis. | - The maximum period of performance is 10 years.  
- The maximum allowable funding for the entire period of performance is $25,000,000 in total costs.  
- Indirect costs may be proposed in accordance with your institution’s negotiated rate agreement. Note that only $5M total funding (direct and indirect costs) allocated for this award will be from the FY21 NFRP budget; the balance is contingent upon receipt of sufficient congressional appropriations to the NFRP in future years. | Pre-application (Pre-Proposal):  
September 17, 2021  
5:00 p.m. Eastern time (ET)  
Invitation to Submit an Application: September 24, 2021  
Application: October 29, 2021  
11:59 p.m. ET |

**Fiscal Year 2021 Neurofibromatosis Research Program (NFRP)**  
Reference Table of Award Mechanisms and Submission Requirements